QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-angiodynamics-maintains-14-price-target

HC Wainwright & Co. analyst Yi Chen reiterates AngioDynamics (NASDAQ:ANGO) with a Buy and maintains $14 price target.

 angiodynamics-secures-ce-mark-approval-in-europe-for-alphavac-f18-system

The CE Mark for the AlphaVac F1885 System expands treatment options for healthcare professionals in the EU by offering a tool t...

 angiodynamics-apex-av-trial-results-assessing-alphavac-f18-system-for-treatment-of-pulmonary-embolism-presented-at-scai-2024-scientific-sessions

New data finds AlphaVac F1885 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides signifi...

 insiders-buying-zumiez-and-3-other-stocks

Although U.S. stocks closed little changed on Monday, there were a few notable insider trades.

 oppenheimer-upgrades-angiodynamics-to-outperform-announces-12-price-target

Oppenheimer analyst Steven Lichtman upgrades AngioDynamics (NASDAQ:ANGO) from Perform to Outperform and announces $12 price ...

 medical-devices-focused-angiodynamics-unveils-upbeat-2024-financial-outlook-stock-soars

FDA grants 510(k) clearance to AngioDynamics' AlphaVac F1885 System for pulmonary embolism. Expanded indication broadens tr...

 angiodynamics-q3-adjusted-eps-016-misses-013-estimate-sales-7518m-miss-7573m-estimate

AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.1...

 angiodynamics-secures-510k-clearance-for-alphavac-f1885-system-in-treatment-of-pulmonary-embolism

The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for the treatment of PE, which broadens the...

 earnings-scheduled-for-april-4-2024

Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on r...

 angiodynamics-resolves-decade-long-patent-litigation-with-becton-dickinson-in-settlement-agreement

AngioDynamics resolves decade-long patent litigation with Becton, Dickinson in landmark settlement, streamlining legal expenses...

Core News & Articles

Under the terms of the settlement, BD will grant a license to AngioDynamics under certain of BD's port patents and AngioDyn...

 angiodynamics-announces-sale-of-picc-and-midline-product-portfolios-to-spectrum-vascular-for-45m

Portfolio optimization enhances strategic focus and follows initiative to restructure manufacturing footprintCompany to discont...

 angiodynamics-announces-fda-510k-clearance-of-auryon-xl-radial-access-catheter-to-treat-peripheral-arterial-disease

225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate ...

 raymond-james-maintains-outperform-on-angiodynamics-lowers-price-target-to-10

Raymond James analyst Jayson Bedford maintains AngioDynamics (NASDAQ:ANGO) with a Outperform and lowers the price target fro...

 robinhood-to-rally-around-18-here-are-10-top-analyst-forecasts-for-monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 hc-wainwright--co-maintains-buy-on-angiodynamics-lowers-price-target-to-18

HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $2...

 why-applied-therapeutics-shares-are-trading-lower-by-over-35-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Applied Therapeutics, Inc.